InflaRx N.V.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving InflaRx N.V. now
Current reporting with the operating signal separated from the noise.
InflaRx N.V.: InflaRx Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
The story matters when it changes InflaRx N.V.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.InflaRx N.V. Receives European Commission Approval for GOHIBIC® (vilobelimab) and Achieves Key Development Milestones in Clinical Trials
The story matters when it changes InflaRx N.V.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.InflaRx N.V. Initiates Phase 2a Trial for INF904 in Chronic Spontaneous Urticaria and Hidradenitis Suppurativa
The story matters when it changes InflaRx N.V.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest IFRX filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
InflaRx N.V., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →